Economic and psychosocial Impact of rotavirus infection in Spain: A literature review

Aldeán, Javier Álvarez; Arı́stegui, Javier; López-Belmonte, Juan Luis; Pedrós, Montse; Sicilia, José García

doi:10.1016/j.vaccine.2014.04.058

Cited by 26 publications

(28 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Europe, rotavirus represents 14% to 54% of all admissions for AGE in this group. 4,6,21 This variability constitutes a limitation when making comparisons and is most likely due to differences in study design, coding methods, access to health care, disease management, data sources, coverage and representativeness of surveillance systems, and the years and geographic areas included. Moreover, rotavirus possesses significant genetic diversity that can cause changes in its antigenicity and pathogenic ability.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Decline in rotavirus hospitalizations following the first three years of vaccination in Castile-La Mancha, Spain

Redondo¹,

Cano

Simón

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Rotavirus is a major burden on the Spanish Healthcare System. Rotarix Ò and RotaTeq Ò were simultaneously commercialized in Spain by February, 2007. The objective is to analyze the incidence and seasonality of rotavirus hospitalizations (RH) in Castile-La Mancha (CLM), following the first 3 y of commercialization. A cross-sectional study of the hospital discharge registry's Minimum Basic Data Set (

show abstract

Section: Discussionmentioning

confidence: 99%

“…5 The disease costs the Spanish national health system EUR 28 million a year. 6 The vaccines Rotarix Ò and RotaTeq Ò were first commercialized in Spain in July, 2006, andFebruary, 2007, respectively. 7 .…”

Section: Introductionmentioning

confidence: 99%

Decline in rotavirus hospitalizations following the first three years of vaccination in Castile-La Mancha, Spain

Redondo¹,

Cano

Simón

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…However, other factors would be required for a full analysis of the cost-effectiveness of vaccination, particularly; the cost of the vaccine program and indirect cost savings from prevention of lost productivity. It has been estimated that when a child is sick by rotavirus, a parent has to miss work an average of 4 days, due to child care at home or in the hospital [16]. In addition, other expenses for the treatment of symptoms such us serum or diapers were not included.…”

Section: Discussionmentioning

confidence: 99%

“…It was estimated that the annual cost for the Spanish national health system is approximately €28 million, and causes productivity loss in two thirds of parents [16]. However, limited information is available regarding the direct economic impact of the vaccination.…”

Section: Introductionmentioning

confidence: 99%

Long-term impact of self-financed rotavirus vaccines on rotavirus-associated hospitalizations and costs in the Valencia Region, Spain

et al. 2017

View full text Add to dashboard Cite

BackgroundRotavirus vaccines are available in Spain from 2007. They are recommended by the Spanish Pediatric Association, but not funded by the National Health System (NHS) and its coverage rate reached 40-50%. The hospitalization rate reduction of rotavirus caused gastroenteritis (RVAGE) directly attributable to vaccination remains unclear due to the large differences described in published studies, ranging from 14 to 44.5% in children <5 years of age, even with similar vaccination coverage. These results could be partly explained by variability in hospitalization policies, different study designs and the timeframe of observation. In addition, the direct economic impact of the reduction of hospitalizations has never been estimated. Therefore, there is a need to analyze the long-term impact of rotavirus vaccines on RVAGE and all cause gastroenteritis (AGE) hospitalizations and the national health system associated costs, minimizing potential confounders or biases.MethodsA population-based, ecological study using the hospital discharge registry’s Minimum Basic Data Set (MBDS) and the vaccine register (SIV) was performed, among Valencia Region’s children <5 years old, during 2002 - 2015. RVAGE and AGE hospitalization risk was analyzed by vaccine coverage and adjusted by the total hospitalization rate for all causes to avoid external biases. The impact of AGE-associated health care utilization in prevaccine (2003–2006) versus postvaccine (2008–2014) years was also assessed.ResultsAfter vaccines licensure, the incidence of RVAGE-associated hospitalizations decreased markedly. A general vaccine coverage-related reduction in RVAGE or AGE-hospitalizations risk was observed in all age groups. Compared with unvaccinated children, RVAGE hospitalization risk decreased by 67% (95% CI: 55-67), 71% (95% CI: 58-81) and 68% (95% CI: 18-92) in children 0, 1 and 4 years of age, respectively, with a vaccination coverage between 40 and 42%. Overall, the hospital related costs were reduced around EUR 6 Mill per 105 children in 7 years.ConclusionsDespite the low-medium vaccine coverage, the introduction of rotavirus vaccines had a specific coverage-related response impact in the hospitalizations for RVAGE and AGE in children <5 years and their use substantially reduced hospital related costs. The model used reassures that the estimated impact is due to the vaccination and not to other external factors.Electronic supplementary materialThe online version of this article (doi:10.1186/s12879-017-2380-2) contains supplementary material, which is available to authorized users.

show abstract

“…6 In Spain, rotavirus AGE represents 14% to 30% of all cases of AGE and requires hospitalization in 25% of cases. 7 As of January, 2015, 13 countries in the WHO European Region (Armenia, Austria, Belgium, Estonia, Finland, Georgia, Germany, Israel, Luxembourg, Moldova, Norway, United Kingdom, and Uzbekistan) had already included rotavirus vaccines into their national immunization programs. 8 Reductions in hospitalizations due to rotavirus AGE have been reported in many countries in Europe [9][10][11][12][13][14][15][16] and mathematical models have calculated a huge impact on the burden of rotavirus disease.…”

Section: Introductionmentioning

confidence: 99%

Impact of vaccination uptake on hospitalizations due to rotavirus acute gastroenteritis in 2 different socioeconomic areas of Spain

Sánchez

Nogueira

Forte

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Rotavirus is the leading cause of hospitalization due to acute gastroenteritis (AGE) in infants and toddlers. However, rotavirus vaccination has been associated with a decline in hospitalization rates due to rotavirus AGE. A descriptive retrospective study was conducted to analyze the impact of rotavirus vaccination on the rate of hospitalizations due to AGE among children ≤2 years old in 2 areas of the province of Almería, Spain. After eight years of rotavirus vaccination, rates of hospitalizations due to rotavirus AGE are diminished. This decline is closely related to vaccine coverage in the studied areas.

show abstract

Economic and psychosocial Impact of rotavirus infection in Spain: A literature review

Cited by 26 publications

References 45 publications

Decline in rotavirus hospitalizations following the first three years of vaccination in Castile-La Mancha, Spain

Decline in rotavirus hospitalizations following the first three years of vaccination in Castile-La Mancha, Spain

Long-term impact of self-financed rotavirus vaccines on rotavirus-associated hospitalizations and costs in the Valencia Region, Spain

Impact of vaccination uptake on hospitalizations due to rotavirus acute gastroenteritis in 2 different socioeconomic areas of Spain

Contact Info

Product

Resources

About